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A B S T R A C T
The current availability of new Poly(ADP-ribose) Polymerase (PARP)-inhibitors for the treatment of ovarian
cancer patients independently of the presence of a BRCA pathogenic variant, together with the validation of
somatic test for the analysis of BRCA1/2 genes, involves the need to optimise the guidelines for BRCA testing.
The AIOM-SIGU-SIBIOC-SIAPEC-IAP Italian Scientific Societies, in this position paper, recommend the im-
plementation of BRCA testing with 2 main objectives: the first is the identification of ovarian cancer patients
with higher probability of benefit from specific anticancer treatments (test for response to therapy); the second
goal, through BRCA testing in the family members of ovarian cancer patients, is the identification of carriers of
pathogenic variant, who have inheredited predisposition to cancer development (test for cancer risk). These
individuals with increased risk of cancer, should be encouraged to participate in dedicated high-risk surveillance
clinics and specific risk-reducing measures (primary and/or secondary prevention programs).
1. Introduction
The AIOM-SIGU-SIBIOC-SIAPEC-IAP Recommendations represent a
position paper for the implementation of BRCA1/2 testing in ovarian
cancer patients and their relatives.
This paper, based on expert opinion, reflects the need to update the
previous recommendations published in 2016 (Pinto et al., 2016) and to
optimise the guidelines for BRCA testing, taking into account the cur-
rent availability of new Poly(ADP-ribose) Polymerase (PARP)-inhibitors
that have been approved for the treatment of ovarian cancer patients
independently of the presence of a BRCA pathogenic variant, and fol-
lowing the validation of somatic test for the analysis of BRCA1/2 genes.
These recommendations are focused on the implementation of
BRCA testing for the identification of:
a) ovarian cancer patients with higher probability of response to spe-
cific anticancer treatments (test for response to therapy);
b) family members of ovarian cancer patients, carriers of pathogenic
variant, who have inheredited predisposition to cancer development
(test for cancer risk). These individuals with increased risk of cancer,
should be encouraged to participate in dedicated high-risk follow-up
clinics and specific risk-reducing measures (primary and/or sec-
ondary prevention programs).
2. The need of implementation of BRCA testing
2.1. BRCA1/2 predictive testing to estimate the cancer treatment efficacy
Retrospective studies have highlighted that ovarian carcinoma pa-
tients, carrying a constitutional (germline) BRCA pathogenic variant,
show an increased pharmacological sensitivity to combination thera-
pies containing platinum derivatives (Alsop et al., 2012; Bolton et al.,
2012; George et al., 2017), even when administered at high doses, as
usually during intraperitoneal chemotherapy, as well as sensitivity to
pegylated liposomal doxorubicin and trabectedin (Safra et al., 2011;
Monk et al., 2016). Moreover, it has been shown that BRCA gene pa-
thogenic variants, whether constitutional or somatic, represent a pre-
dictive biomarker of higher sensitivity to treatment with PARP in-
hibitors, a class of pharmacological agents involved in the single-strand
DNA breaks repair, in patients with advanced ovarian cancer. The ef-
ficacy of PARP inhibitors as therapeutic option in ovarian cancer is due
to ‘synthetic lethality’, which occurs in cells with an inactive double-
strand DNA repair mechanism mediated by homologous recombination
(HR), where the BRCA1/2 proteins play an essential role (Drost and
Jonkers, 2014; George et al., 2013; Cancer Genome Atlas Research
Network, 2011; Wiggans et al., 2015; Cortesi et al., 2018). The loss of
function due to constitutional or somatic BRCA gene pathogenic var-
iants can be one of the major, although not exclusive, causes of HR
dysfunction (Curtin, 2012; Hilton et al., 2002).
The prevalence of constitutional BRCA pathogenic variants in
ovarian cancer patients is> 10%, independently of age of diagnosis
and family history (Soegaard et al., 2008). Actually, approximately
25% of women carrying pathogenic BRCA variants have a diagnosis of
ovarian carcinoma over 60 years of age. The prevalence of pathogenic
variants progressively increases to 17–20% in patients with serous
ovarian carcinoma (Alsop et al., 2012; Cancer Genome Atlas Research
Network, 2011), to 23–25% if high-grade (Rust et al., 2018) and to
30–40% if the disease is platinum-sensitive.
Following clinical trials, the PARP inhibitor olaparib has been re-
gistered in October 2014 by EMA (European Medicines Agency) “as
maintenance therapy of patients with platinum-senstive relapsed BRCA-
mutated (with germinal and/or somatic mutation) high-grade serous
epithelial ovarian, Fallopian tube or primary peritoneal cancer who are
in a complete or partial response to platinum-based chemotherapy”
(Ledermann et al., 2014; Anon., 2019a). The Italian Medicines Agency
(AIFA) has approved the drug with the same indication, stating that
“the treatment with olaparib must be started and be monitored under
the supervision of a doctor experienced in the use of anti-cancer med-
icines. Patients must have a confirmed breast cancer susceptibility gene
mutation (BRCA) (within the germline or the tumor tissue) before
starting olaparib treatment. The evaluation of BRCA mutational status
must be performed by a laboratory with expertise using a validated test
method” (Anon., 2015).
Niraparib, another PARP inhibitor, is currently available in a few
countries, including Italy, as “monotherapy for the maintenance treat-
ment of adult patients with platinum-sensitive relapsed high-grade
serous epithelial ovarian, fallopian tube, or primary peritoneal cancer
who are in response (complete or partial) to platinum-based che-
motherapy” (Anon., 2018), independently of the presence of BRCA
mutations.
EMA has recently approved the use of:
- olaparib, independently of BRCA mutational status, (on the basis of
randomized prospective clinical trials that have demonstrated the
benefit of these drugs as maintenance therapy in the overall population
of patients with relapsed platinum-sensitive disease);
- another PARP inhibitor, rucaparib, as monotherapy treatment of
platinum-sensitive patients with germinal and/or somatic BRCA pa-
thogenic variant, associated with advanced high-grade ovarian cancer,
fallopian tube, or primary peritoneal cancer, who have been treated
with at least two prior platinum-based chemotherapy, and who are not
candidates for further platinum-based chemotherapy (Anon., 2019b),
on the basis of the ARIEL 2 study results. Furthermore, the EMA’s
Committee for Medicinal Products for Human Use (CHMP) adopted a
positive opinion on rucaparib (December 2018) for an additional in-
dication as maintenance treatment of adult patients with platinum-
sensitive relapsed high-grade epithelial ovarian, fallopian tube, or pri-
mary peritoneal cancer who are in response (complete or partial) to
platinum-based chemotherapy (on the basis of the ARIEL 3 study
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results).
Although these new therapeutic options have demonstrated their
efficacy even in patients not carrying BRCA gene pathogenic variants
(wild type), it is nevertheless important to investigate the BRCA status
in all ovarian cancer patients (with the exception of mucinous and
borderline tumors) for the following reasons:
a) patients with test positive for BRCA1/2 pathogenic variants show a
greater benefit from the treatment with PARP inhibitors when
compared to patients not carrying such variants (Staropoli et al.,
2018);
b) the use of olaparib as maintenance treatment after a first-line che-
motherapy in patients with BRCA pathogenic variants has been as-
sociated, in a phase III randomized clinical trial, with a statistically
significant improvement in progression-free survival (PFS); indeed,
the median PFS was 13.8 months in patients receiving placebo and
has not been reached after 3 years in those patients receiving ola-
parib (HR 0.30; 95% CI 0.23- 0.41; p < 0.001). Thus, it will be
crucial to be informed on the BRCA mutational status at the time of
initial diagnosis, leading to the most appropriate first-line treatment
approach (Moore et al., 2018);
c) BRCA-positive patients affected by ovarian cancer should undergo
active surveillance for the risk of developing secondary cancers
(breast cancer and other heredo-familial cancers associated with
BRCA gene pathogenic variants);
d) the inability to repair chemotherapy-induced DNA damage confers a
significantly better prognosis in BRCA-positive patients with ad-
vanced disease when compared to wild type patients;
e) the important implications of cancer risk-assesment and prevention
among family members, especially in the case of a positive test re-
sult (Anon., 2019a; Mirza et al., 2016; Anon., 2019c; Pujade-
Lauraine et al., 2017).
Based on these observations, it is important to offer the BRCA test at
the time of initial diagnosis to all patients with non-mucinous and non-
borderline ovarian epithelial carcinoma, fallopian tube carcinoma and
primary peritoneal carcinoma (Fig. 1).
BRCA testing should be proposed at the time of initial diagnosis,
providing appropriate information on all aspects associated with the
results and respecting the will of the patients (Table 1).
2.2. BRCA1/2 testing for the identification of hereditary cancer
predisposition
As above mentioned, a positive test result for a BRCA pathogenic
variant in ovarian cancer patients enables the access of their relatives to
cancer genetic counseling and to risk- assessment tests, aimed to verify
the presence of the familial genetic alteration. In the case of a positive
test result, programs for risk reduction and/or early detection of
heredo-familial cancers associated with BRCA gene pathogenic variants
are implemented (Fig. 1).
In the United States, where BRCA testing has become universal for
all ovarian cancer patients over the last few years, epidemiologists es-
timated that risk reduction strategies (medical or surgical) applied to
healthy family members tested positive could lead to a reduction in
ovarian cancer incidence by 40% in 10 years (Bayraktar and Arun,
2017). This accomplishment, in a tumor for which still nowadays
simple and effective prevention and screening methods are not
Fig. 1. It is initially preferred to search the BRCA1/2 pathogenic variants on tumor tissue, because the BRCA testing on peripheral blood is able to detect only
constitutional/hereditary variants. The identification of a pathogenic variant, somatic or germline, allows to identify the ovarian cancer patients with higher
probability of response to specific anticancer treatments. In the case of a constitutional variant, in addition to predictive informations, the patient will gain the access,
through the cancer genetic counseling, to test for cancer risk (surveillance programs and risk reduction strategies).
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available, is exceptionally important.
If the reference laboratory exclusively performs the test on periph-
eral blood, for patients with a negative constitutional/germline test
result, it will be necessary to refer the tumor tissue to another labora-
tory for the quest of somatic BRCA1/2 variants.
3. Types of BRCA testing
Currently, the BRCA test in peripheral blood (“germline or con-
stitutional test”) for the detection of constitutional pathogenic variants
is performed in most laboratories using well-established techniques,
namely by next-generation sequencing (NGS) eventually followed by
Sanger sequencing for variant validation.
The sequencing analysis of the coding portion and exon/intron
junctions of BRCA1 and BRCA2 genes allows the detection of point
variations (single nucleotide substitutions and insertions/deletions of
one or a few bases) in the DNA sequence and encompasses about 90% of
BRCA pathogenic variants. In order to maximize sensitivity, the test
must include the search for large genomic rearrangements (i.e., dele-
tions or duplications of one or more exons, or of the whole gene), which
account for a variable proportion of constitutional BRCA variants across
populations, usually not exceeding 10%. Analyses using NGS methods
allow to predict with a certain degree of reliability large rearrange-
ments in BRCA1/2, which are usually confimed by techniques such as
Multiplex Ligation Probe dependent Amplification (MLPA) or Multiplex
Amplicon Quantification (MAQ). Generally, MLPA and MAQ should be
complementarily used, in order to circunvent technical faults
(Scaglione et al., 2018; Concolino et al., 2018).
According to available data, it is expected that two thirds of pa-
thogenic BRCA variants identified in patients affected by ovarian cancer
are constitutional (present in every cell of the individual), inherited
from one parent or arisen de novo (less than 1% of cases) and, therefore,
transmissible to the offspring (50% probability for each child). On the
other hand, in one third of cases the pathogenic variants are exclusively
somatic and thus confined to tumor tissue (George et al., 2013; Cancer
Genome Atlas Research Network, 2011).
The BRCA test conducted on tumor tissue (“somatic test”) can also
identify the variants acquired as somatic mutations in addition to
constitutional defects. Hence, in the event of a positive result, the al-
teration must be verified in peripheral blood in order to ascertain its
constitutional origin. The somatic analysis enables physicians to iden-
tify a fraction of around 7% of ovarian cancer patients with a patho-
genic BRCA variant that would remain unknown if only test in per-
ipheral blood is performed (Ellison et al., 2018). Nonetheless, in spite of
several existing commercial systems that are CE-IVD (In Vitro Diag-
nostics) certified for the BRCA1/2 analysis on tumor tissue, many of
them are currently not equipped with bioinformatic software applica-
tions dedicated to the implementation and interpretation of BRCA
analysis. Such systems are not accurate for the assessment of large re-
arrangements, while resulting to be as reliable as blood tests for point
variant identification (Ellison et al., 2018; Capoluongo et al., 2017).
When prescribing the somatic test the following issues are to be
considered.
1 The surgical sample submitted for molecular analysis must be as-
sumed as appropriate (≥20% of neoplastic cells in the specimen)
(Capoluongo et al., 2017) by the pathologist, who must evaluate the
characteristics of the tissue block under examination and consider, if
necessary, manual macrodissection to select areas with higher
tumor cellularity within the specimen.
2 NGS methods allow to detect germline variants also in tumor tissue,
without any major problems (Ellison et al., 2018), while on the
other hand fail to identify medium- or large-sized rearrangements as
well as low frequency allelic variants in the specimen under ex-
amination.
3 Lastly, at present, only few labs conduct the test in tumor tissue,
while an ever increasing number of them perform the test in per-
ipheral blood.
In terms of a proper implementation of BRCA testing, it is necessary
that laboratories:
a have proven experience of test validation;
b take part in approved external quality control programs.
In any event, there are specific methodological recommendations
for the development of an NGS data analysis workflow on ovarian
tumor tissue for the detection of BRCA variants (Ellison et al., 2018;
Capoluongo et al., 2017).
Furthermore, the use of ad hoc standards for each type of analytical
process is crucial also in terms of a proper bioinformatics analysis
(Zhong et al., 2018). Not least, it is recalled that there is a need of an
appropriate tissue storage according to pre-analytical procedures that
may provide the best preservation of DNA (Capoluongo et al., 2017;
Zhong et al., 2018; Anon., 2019d).
The panel does consider that both the BRCA tests, in tumor tissue
Table 1
Summary of recommendations for the implementation of BRCA testing in
ovarian cancer patients and their relatives.
It is important to offer the BRCA testing to all patients with non-mucinous and non-
borderline ovarian epithelial carcinoma, fallopian tube carcinoma and primary
peritoneal carcinoma.
BRCA testing should be proposed at the time of initial diagnosis, providing
appropriate information on all aspects associated with the results and respecting
the will of the patients.
Reasons:
a) Patients with test positive for BRCA1/2 pathogenic variants show a greater benefit
from the treatment with PARP inhibitors when compared to patients not carrying
such variants;
b) BRCA-positive patients affected by ovarian cancer should undergo active
surveillance for the risk of developing secondary cancers (breast cancer and other
heredo-familial cancers associated with BRCA gene pathogenic variants);
c) The inability to repair chemotherapy-induced DNA damage confers a significantly
better prognosis in BRCA-positive patients with advanced disease when
compared to wild type patients;
d) BRCA-positive test in ovarian cancer patients has important implications of cancer
risk-assesment and prevention among relatives.
Table 2
Summary of recommendations for the interpretation of BRCA genetic variants
and management of results in the care & treatment pathway.
a) It is initially preferred to search the BRCA1/2 pathogenic variants on tumor tissue.
In one third of cases the BRCA pathogenic variants are exclusively somatic. Thus,
the BRCA test conducted on tumor tissue (“somatic test”) can also identify the
variants acquired as somatic mutations in addition to constitutional defects.
b) In order to maximize sensitivity, the test must include the search for large genomic
rearrangements (i.e., deletions or duplications of one or more exons, or of the
whole gene), which account for a variable proportion of constitutional BRCA
variants across populations, usually not exceeding 10%.
c) The surgical sample submitted for somatic molecular analysis must be assumed as
appropriate (≥20% of neoplastic cells in the specimen) by the pathologist, who
must evaluate the characteristics of the tissue block under examination and
consider, if necessary, manual macrodissection to select areas with higher tumor
cellularity within the specimen.
d) NGS methods allow to detect germline variants also in tumor tissue, without any
major problems, while on the other hand fail to identify medium- or large-sized
rearrangements as well as low frequency allelic variants in the specimen under
examination.
e) It is necessary that laboratories have proven experience of test validation and take
part in approved external quality control programs.
f) If the workflow begins with the test in peripheral blood, in case of non-informative
result in a patient eligible to receive the treatment based on PARP inhibitor only
when the presence of a pathogenic variant is demonstrated in one BRCA gene, it
is necessary to refer the tumor tissue to a qualified laboratory for the quest of
somatic variants.
g) For the interpretation of BRCA genetic variants it is important that laboratories use
the updated criteria developed by the Evidence-based Network for the
Interpretation of Germline Mutant Alleles (ENIGMA), available on the
consortium website.
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and blood, may be used, but it is preferrable, whenever possibile, to
perform the somatic test in the first instance, taking into consideriation,
in any event that, independently of the type of sample used, quality
standards are to be met along and data analysis and interpretation
expertise are required.
If the workflow begins with the test in peripheral blood, in case of
non-informative result (no pathogenic variant detected) in a patient
eligible to receive the treatment based on PARP inhibitor only when the
presence of a pathogenic variant is demonstrated in one BRCA gene, it
is necessary to refer the tumor tissue to a qualified laboratory for the
quest of somatic variants.
4. Interpretation of BRCA genetic variants
The spectrum of allelic variations of the BRCA1 and BRCA2 genes is
very broad. Indeed, variant classification is an important aspect of the
BRCA testing process, particularly when considering that quite often
clinical testing detects genetic alterations not reported in the scientific
literature. Therefore, although several standards exist for the classifi-
cation of constitutional BRCA variants (Richards et al., 2015), it is
important that laboratories use the updated criteria developed by the
Evidence-based Network for the Interpretation of Germline Mutant Alleles
(ENIGMA), available on the consortium website (Anon., 2019e), which
are gene specific and based on a broad consulation of international
experts. ENIGMA classifies variants in five groups, according to IARC
recommendations (Plon et al., 2008): benign, likely benign, uncertain,
likely pathogenic and pathogenic.
It is important to underline that the mentioned criteria have been
developed in order to define the meaning of the variants of BRCA genes
as predictive of hereditary risk. At this time, information on the effect of
the different BRCA variants in terms of response to treatment is much
more limited and specific classification criteria for this purpose have
not yet been developed.
It is therefore necessary that laboratory make their protocols, in-
cluding the interpretation process, available, and indicate in the test
report the clinical significance of the BRCA gene variants identified
along with a list of the essential information used for the classification
(Claustres and KožichV, 2014). In this regard, laboratories should take
part in external quality control programs and contribute to a systematic
and centralized, national and international, collection of all BRCA
variants observed with the aim to improve their classification (Wallis
et al., 2019), as concerned both the definition of hereditary risk and the
prediction of response to anticancer treatments.
Furthermore, it is also recommended that the variants classification
is periodically verified. Each reclassification must be notified to the
referring physician, who is required to inform the person to whom the
test has been given (Table 2).
5. Availability of BRCA testing and management of results in the
care & treatment pathway
The traditional pre-test models of cancer genetic counseling devel-
oped in the risk-assessment setting are currently insufficient to meet the
increasing number of BRCA test requests, particularly when the test for
genetic predisposition has also a predictive value for treatment, which
needs to be determined in a short time.
Although the optimal model of genetic counseling for cancer risk
assessment involves detailed information and discussion of the genetic
aspects right from the pre-test stage, the need to obtain test results in a
timely manner in order to implement treatment planning implies that
also oncologists and gynecologists experienced in oncology can directly
request the BRCA test to the laboratory. Even when the test is per-
formed in the cancer treatment setting, the arrangement of compre-
hensive care pathways is mandatory, to ensure the correct interpreta-
tion of the results for clinical purposes, the correct way to manage
family members at risk if a hereditary pathogenic variant is identifed
and the correct genetic assessment of cases with a noninformative
BRCA test result (Claustres and KožichV, 2014; Wallis et al., 2019).
Each center must provide clear indications of the management
pathways to the patients and their relatives, outlining the duties and
responsibilities of the oncology team, of the laboratory and of the
clinical cancer genetics team across the different phases of the defined
care pathway.
In the absence of recognized standards, one should consider sub-
mitting these pathways to verification via planned audits, with the aim
to improve service quality. It is desirable that local health authorities
render the BRCA test free of charge for healthy relatives of patients
carrying an identified BRCA1/2 pathogenic variant and, eventually,
offer for free the prevention programs to subjects harboring the pa-
thogenic variant, through the introduction of a code exempt for her-
editary genetic diseases.
6. Essential items of the informed consent
The BRCA test for prognosis and prediction of response may be
prescribed by clinical geneticists, oncologists and gynecologists with
oncologic expertise who have the responsibility to provide appropriate
information to the patients on the genetic aspects associated with the
results.The information provided to the patient should cover the po-
tential benefits in terms of prognostic and therapeutic significance,
together with the possibility of detecting a high secondary cancer risk
and the presence of a cancer predisposition in her relatives. The timing
at which informed consent to genetic testing is obtained, as well as the
modalities, must respect the will of the patient, who should be given the
possibility to discuss all the different implications of genetic testing,
such as whether or not to tell other family members about the test re-
sults, before taking a decision.
Physicians who prescribe a BRCA test should abide to an appro-
priate communication and protocols for collection of specific written
informed consent, possibly using ad hoc information material.
Oncologists and gynecologists with oncologic expertise who do not
have experience in cancer genetics must follow a training program
which includes ethical aspects of BRCA testing.
Finally, the care pathway must clearly identify the cancer genetics
team which the patient is referred to, when requiring a deeper eva-
luation of the genetic aspects, before deciding whether or not to un-
dergo the test, as well as in particular circumstances, such as families
with nonspecific hereditary predisposition to cancer.
7. Conclusion
In conclusion, the knowledge of the prognostic and predictive role
of individual BRCA mutational status is a rapidly evolving field.
In light of the recent technological advances and therapeutic de-
velopments, these recommendations by the Italian scientific societies,
highlight the importance of the implementation of BRCA testing in the
management and treatment pathways of ovarian cancer patients and
their relatives. The identification of BRCA1/2 pathogenic variants have
therapeutic implications in addition to cancer risk assessment and allow
us to obtain the information to improve the outcome of medical treat-
ments, to promote specific strategies of risk reduction and finally to
improve the survival of ovarian cancer patients and the incidence of the
disease in the population.
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